No.

PRODUCTS

CAS No.

INDICATIONS

Remark

1

Ibrutinib

936563-96-1                                               

Oncology

DMF

2

Ruxolitinib

941678-49-5

Myelofibrosis

DMF*

3

Elagolix

834153-87-6

Endometriosis,Uterine leiomyoma

TDP

4

Relugolix

737789-87-6

Endometriosis
Uterine leiomyoma, Prostate cancer

TDP